Biocon Knocked Back By FDA On Human Insulin

Biosimilar Filing Receives CRL Citing Need For More Data And Facility Remediation

 
• By David Wallace
  
Insulin wireframe of syringe and vial
Biocon has received a setback on human insulin • Source: Shutterstock

More from Biosimilars

More from Products